, In Vivo Therapeutics Core (IVTC) The In Vivo Therapeutics Core (IVTC) is a multi-faceted shared resource facility of the Indiana University Melvin and Bren Simon Cancer Center (IUSCC) that was established to facilitate the discovery and testing of novel pharmacological & cellular therapies. The IVTC is divided into five hubs of research expertise: state-of-the-art equipment for cancer research, breeding of specialized mouse strains, preclinical toxicity and efficacy testing in xenograft models, patient-derived xenografts, and hematopoietic stem-cell transplant studies. Importantly, the IVTC is structured in a way to provide the necessary infrastructure, oversight, and expertise required to successfully meet the needs of the IUSCC investigators. Given the heavy reliance of IUSCC investigators on services provided by IVTC, there is strong rationale to support this centralized shared resource that will facilitate the discovery of new therapies for cancers prominent in the catchment area of Indiana. In the past year, 67% of IVTC users were peer-reviewed Cancer Center members and accounted for 94% of the services invoiced. For the majority of IUSCC members, utilization of mouse models is an essential component of their ongoing research activities focused on development of novel therapies for liquid and solid tumors. To support the needs of the membership, the Aims of the IVTC are: (1) to maintain on-site breeding colonies of mice and establish patient-derived xenografts essential for the exploration, testing, and refinement of novel cancer therapeutics; (2) to provide specialized core services and technology applicable to in vivo studies; and (3) to serve as a consultation and educational resource for IUSCC investigators and trainees. Specifically, the IVTC manages the Radiation facility and will perform irradiation services needed for in vitro and in vivo experiments, including hematopoietic stem-cell transplantations. The IVTC will coordinate all aspects of procedures and provide assistance with experimental design, regulatory requirements, methodology, and data interpretation for each research hub. Shared equipment maintained by the IVTC provides investigators with access to a recently acquired IncuCyteZOOM Live-Cell Imaging System and a hypoxia workstation which are both available for direct use or in partnership with technical staff in the IVTC. In addition, the IVTC will work with IUSCC research teams to coordinate timely delivery of mice and samples to other Core facilities within the IUSCC and the IUSM. As a centralized facility, the IVTC will provide IUSCC investigators advanced resources for analytical and investigational studies essential for the preclinical validation of novel drug targets and biomarkers of cancer so that innovative investigator-initiated trials can be successfully developed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082709-20
Application #
9793158
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Pin, Fabrizio; Barreto, Rafael; Kitase, Yukiko et al. (2018) Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle 9:685-700
Robertson, Michael J; Stamatkin, Christopher W; Pelloso, David et al. (2018) A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. J Immunother 41:151-157
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10
Filley, Anna; Henriquez, Mario; Bhowmik, Tanmoy et al. (2018) Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J Neurooncol 137:469-479
Sishtla, Kamakshi; Pitt, Natalie; Shadmand, Mehdi et al. (2018) Observations on spontaneous tumor formation in mice overexpressing mitotic kinesin Kif14. Sci Rep 8:16152
Koh, Byunghee; Abdul Qayum, Amina; Srivastava, Rajneesh et al. (2018) A conserved enhancer regulates Il9 expression in multiple lineages. Nat Commun 9:4803
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517

Showing the most recent 10 out of 256 publications